National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 14 of 41
Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults
NCT01783977
Malaria Transmission Studies in Mali
NCT01829737
Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
NCT01504841
Idebenone for Primary Progressive Multiple Sclerosis
NCT01854359
Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
NCT04870138
Sirolimus for Eosinophil-Associated Gastrointestinal Disorders
NCT01814059
Intranasal AD4-H5-VTN as an Adenovirus Vaccine
NCT01806909
LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine
NCT01751048
Validation of Gene Expression Markers of Renal Allograft Functional Decline
NCT01782586
Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
NCT01790594
Bone Marrow Stromal Cells for Inflammatory Bowel Diseases
NCT01851343
Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3
NCT01336699
Effect of Filarial Infection on Immune Responses in Latent Tuberculosis
NCT01547884
Sildenafil for PNTM Infection
NCT01853540
Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations
NCT01746082
Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart
NCT01782300
Combination Therapy for Chronic Hepatitis C Infection
NCT01805882
Testing the AVI-7100 Flu Drug in Healthy Volunteers
NCT01747148
Volunteer Screening for Vaccine and Antivirals Clinical Trials
NCT01593709
Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults
NCT01730144
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
NCT01552369
Tdap Vaccine in Post-Partum Women
NCT01711645
A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
NCT01654263
Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study
NCT01737710
Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics
NCT01632995
Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines
NCT01674205
Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers
NCT01674218
Clinical Outcomes of People Who Acquired HIV in Early Life
NCT01656564
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
NCT01638559
Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years
NCT01676402
Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73
NCT01592214
Genomics of Kidney Transplantation
NCT01714440
Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients
NCT01672164
Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule
NCT01641991
Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
NCT01552681
Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults
NCT01574638
Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
NCT01505114
Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents
NCT01609998
Gene Expression in HIV and Tuberculosis Co-infection
NCT01611402
H5N1 Vaccination With and Without AS03: Systems Biology Analysis
NCT01573312
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
NCT01404312
Phase I Trial of a Single Dose of CRS3123
NCT01551004
The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children"
NCT01595529
Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
NCT01571414
Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults
NCT01578889
Sanaria™ PfSPZ Challenge Vaccine
NCT01546389
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
NCT01571960
Perceived Barriers to Patient Adherence After Pediatric Solid Organ Transplantation
NCT01370746
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
NCT01482767
Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
NCT01578317
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.